REGN Stock Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Regeneron Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$681.20 |
| 52 Week High | US$1,091.50 |
| 52 Week Low | US$678.40 |
| Beta | 0.080 |
| 1 Month Change | -3.62% |
| 3 Month Change | -33.44% |
| 1 Year Change | -11.42% |
| 3 Year Change | 24.40% |
| 5 Year Change | 102.98% |
| Change since IPO | 66.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| REGN | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | -2.5% | 1.0% | -1.4% |
| 1Y | -11.4% | 11.4% | -1.6% |
Return vs Industry: REGN underperformed the Austrian Biotechs industry which returned 15.5% over the past year.
Return vs Market: REGN underperformed the Austrian Market which returned -1.9% over the past year.
Price Volatility
| REGN volatility | |
|---|---|
| REGN Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in AT Market | 6.2% |
| 10% least volatile stocks in AT Market | 2.1% |
Stable Share Price: REGN's share price has been volatile over the past 3 months compared to the Austrian market.
Volatility Over Time: REGN's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 14,165 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
Regeneron Pharmaceuticals, Inc. Fundamentals Summary
| REGN fundamental statistics | |
|---|---|
| Market cap | €73.03b |
| Earnings (TTM) | €4.46b |
| Revenue (TTM) | €13.27b |
16.2x
P/E Ratio5.5x
P/S RatioIs REGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REGN income statement (TTM) | |
|---|---|
| Revenue | US$13.85b |
| Cost of Revenue | US$6.82b |
| Gross Profit | US$7.03b |
| Other Expenses | US$2.37b |
| Earnings | US$4.65b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 43.26 |
| Gross Margin | 50.75% |
| Net Profit Margin | 33.61% |
| Debt/Equity Ratio | 6.8% |
How did REGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 08:58 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Regeneron Pharmaceuticals, Inc. is covered by 69 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |